Cardioprotective Properties of Omecamtiv Mecarbil against Ischemia and Reperfusion Injury

Omecamtiv mecarbil (OM) is a first-in-class myosin activator. It was developed as a new inotropic therapy option for heart failure and is currently the object of a phase 3 clinical trial program. OM activates ryanodine receptors, which were shown to be involved in cardioprotection induced by conditi...

Descripción completa

Detalles Bibliográficos
Autores principales: Stroethoff, Martin, Behmenburg, Friederike, Meierkord, Simon, Bunte, Sebastian, Mayer, Felix, Mathes, Alexander, Heinen, André, Hollmann, Markus W., Huhn, Ragnar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6463149/
https://www.ncbi.nlm.nih.gov/pubmed/30889854
http://dx.doi.org/10.3390/jcm8030375

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6463149/
https://www.ncbi.nlm.nih.gov/pubmed/30889854
http://dx.doi.org/10.3390/jcm8030375

Ejemplares similares